Akari shareholder-approved 11B share increase for equity plan and director option grant of 1.35M ADSs

Akari Therapeutics Plc

Shareholders approved increase in 2023 Plan share pool by 11,026,000,000 ordinary shares (5,513,000 ADSs) to 19,806,000,000 ordinary shares.
Approved aggregate time-vested option grant of 1,350,000 ADSs (2.7B ordinary shares) to six directors, representing 4.2% of issued share capital.
Re-elected all six director nominees: Hoyoung Huh, Robert Bazemore, James Neal, Sandip Patel, Samir Patel, Abizer Gaslightwala.
Ratified BDO USA as independent auditor for FY2025 and HaysMac as statutory auditor.
Advisory votes on NEO compensation and board remuneration report passed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.